Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerNew strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyMYC, Metabolism, and CancerRedox control of glutamine utilization in cancerStructural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferaseNAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophagesMetabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cellsA H2S-Nampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cellsStructural basis for resistance to diverse classes of NAMPT inhibitorsBig brains, meat, tuberculosis, and the nicotinamide switches: co-evolutionary relationships with modern repercussions?Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening.Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanismEIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibitionDepletion of the central metabolite NAD leads to oncosis-mediated cell death.Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes.Nutritional energy stimulates NAD+ production to promote tankyrase-mediated PARsylation in insulinoma cellsObesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.Nmnat3 Is Dispensable in Mitochondrial NAD Level Maintenance In Vivo.Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomicsMetabolic Response to NAD Depletion across Cell Lines Is Highly VariableNicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expressionSubcellular Distribution of NAD+ between Cytosol and Mitochondria Determines the Metabolic Profile of Human Cells.Comparative Metabolomic Profiling Reveals That Dysregulated Glycolysis Stemming from Lack of Salvage NAD+ Biosynthesis Impairs Reproductive Development in Caenorhabditis elegansThe effector AvrRxo1 phosphorylates NAD in planta.Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.Physiological and pathophysiological roles of NAMPT and NAD metabolism.Targeting metabolic pathways for head and neck cancers therapeutics.Differences in intracellular mobile zinc levels affect susceptibility to plasma-activated medium-induced cytotoxicity.Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
P2860
Q26740187-ACB42B6F-247E-46ED-8CCD-F41DF1D44766Q26745678-715B662F-2BF4-4CD9-A2B2-52C9EDF879EEQ26783555-56820C57-DEA8-4D65-AE26-A80871D3F853Q27005615-2BE0EC39-FBBF-48C9-84F2-73A96199EC96Q27690154-242782D6-F372-499B-AB4A-D9BAFAAD9CAFQ28538761-04DC34E7-464E-4580-AFD9-6539CEA5BAE0Q28542558-1FA6B173-17AD-4423-BF28-8E8FFFCAF910Q28543172-9A7F0762-7764-4A59-ABFB-324E5CF91064Q28543568-9046E256-5F97-4237-A6D5-934A39AD5A22Q28661643-544003C8-AFF7-4E19-8D0F-56FAB6A59B96Q30422519-02CAFACB-FCC4-4219-B3F1-8296281D9DC0Q33583816-9EAD1514-CDA0-42E0-979C-C30BF166D59EQ34077048-1AB41AEF-D416-46AA-B469-FE1F41C5957FQ34332654-098EB417-4A9E-44BF-833C-E34E07497119Q34500782-9E56C6F8-0A2C-4B9E-B203-138BD0AC3320Q34737798-74F90DE0-ED93-42B3-A39F-FD020161874BQ35030829-8F4BAF3E-FE8C-4EF5-ACB6-31139B1EA360Q35112888-7780692E-D240-4E3D-BC5B-BDEA19B509D3Q35392914-F0FDC8E6-C969-4E96-8AE2-EF33279875D2Q35817986-33B34281-7291-4746-86D9-87EE7AF16EE2Q35860727-FB66587C-1029-456F-AD65-0E8FCF39C56EQ35891449-E5DAE05A-5EA4-4300-BB49-EDFDB3666DE1Q36104523-75AD9294-A1E3-48EF-8C4F-0AC56A8B7B5FQ36155272-D3F333EF-A88B-4239-A499-915FA2C6E5F6Q36162234-C56D5496-566B-4CBF-883E-3AB497139DB3Q36282881-9F9C9720-5100-488B-9221-6ED6CB40C943Q36283555-B68E21C6-0254-4774-A83C-8AD2DAF7F57CQ36409276-F992487E-2F4D-4421-8D2C-2762E0C15459Q36739012-6D7A3E53-7910-4EED-8571-489101E7B810Q36771997-A07FF301-5A4A-45DE-B886-01455F7FEAC8Q37230411-DA6C7F6A-2369-447B-96F8-18F6F7AB7089Q37285546-91489D08-CDAA-4302-BD0C-CA494704CB37Q37349113-16661D2D-4AD0-49EB-B8C6-1CE7853AE44DQ37619827-2D2B07B3-3E6F-4CB0-89B4-C0E5A8C8408CQ37626233-DDD271DF-E8E4-4F71-996D-536A3A996E1FQ38405687-FECA8CD9-4260-40E3-BC72-8D3E4B8EC63EQ38555243-01E30C4A-D048-4446-A8B8-CB0F16A764A9Q38640439-15080E55-AC6E-48AD-91C1-29DF1E5678C8Q38711259-E38829E4-5E48-443D-9AA0-92A8990AF333Q38836121-E2D37780-897A-480B-B1E6-1010FC412C27
P2860
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacological inhibition of ...... tential clinical implications.
@ast
Pharmacological inhibition of ...... tential clinical implications.
@en
type
label
Pharmacological inhibition of ...... tential clinical implications.
@ast
Pharmacological inhibition of ...... tential clinical implications.
@en
prefLabel
Pharmacological inhibition of ...... tential clinical implications.
@ast
Pharmacological inhibition of ...... tential clinical implications.
@en
P2093
P2860
P356
P1476
Pharmacological inhibition of ...... tential clinical implications.
@en
P2093
Debra A Young
Genshi Zhao
James Gillig
Karen Huss
Kenneth Roth
Michele C Smith
Ming-Shang Kuo
Robert L Shepard
Sandaruwan Geeganage
P2860
P304
P356
10.1074/JBC.M112.394510
P407
P577
2012-12-13T00:00:00Z